Health Trials

Q702 for the Treatment of Patients With Hematologic Malignancies

ConditionsHematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant HistiocytosisPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPrimary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Follicular LymphomaRecurrent Langerhans Cell HistiocytosisRecurrent Lymphoplasmacytic LymphomaRecurrent Myelodysplastic SyndromeRecurrent MyelofibrosisRecurrent Small Lymphocytic LymphomaRecurrent Waldenstrom MacroglobulinemiaRefractory Chronic Lymphocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Erdheim-Chester DiseaseRefractory Follicular LymphomaRefractory Langerhans Cell HistiocytosisRefractory Lymphoplasmacytic LymphomaRefractory Myelodysplastic SyndromeRefractory MyelofibrosisRefractory Small Lymphocytic LymphomaRefractory Waldenstrom MacroglobulinemiaRosai-Dorfman-Destombes DiseasePrimary Central Nervous System LymphomaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Erdheim-Chester DiseaseRecurrent Fibroblastic Reticular Cell SarcomaRecurrent Histiocytic SarcomaRecurrent Interdigitating Dendritic Cell SarcomaRecurrent Rosai-Dorfman-Destombes DiseaseRefractory Blastic Plasmacytoid Dendritic Cell NeoplasmRefractory Fibroblastic Reticular Cell SarcomaRefractory Histiocytic SarcomaRefractory Interdigitating Dendritic Cell SarcomaRefractory Rosai-Dorfman-Destombes Disease
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic

About this trial

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Eligibility criteria

Qualifiers

PRE-REGISTRATION: Age ≥ 18 years

PRE-REGISTRATION: Not eligible for or have failed therapies with established benefits, at the discretion of the treating physician

Relapsed/refractory patients with Erdheim-Chester disease, Langerhans histiocytosis, histiocytic sarcoma, or other malignant histiocytosis without activating alterations in v-Raf murine sarcoma viral oncogene homolog B (BRAF) or Mitogen-activated protein kinase kinase (MAP2K) oncogenes who have progressed after first line of therapy.

Note: Relapsed is defined as a relapse that occurred after having a response to the last therapy at any point during the treatment. Refractory is no response (stable disease or progressive disease while on therapy) to a given treatment at least after 1 month of being on the given treatment.

Disqualifiers

PRE-REGISTRATION: Myeloproliferative neoplasm (MPN) patients with known active CNS metastases and/or carcinomatous meningitis.

Note: Histiocytosis and lymphoma patients who are on steroids are allowed to enroll

Pregnant persons

Nursing persons

Trial design

Treatments tested in this trial

  • Axl/Mer/CSF1R Inhibitor Q702
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Positron Emission Tomography
  • Survey Administration

Treatment groups

46 Participants
are divided into 1 treatment group

Sponsors and collaborators

Mayo Clinic

Lead sponsor

Source ClinicalTrials.gov